Lercanidipino Stada (Lercanidipine Hydrochloride)

Lercanidipine, the active ingredient in Lercanidipino Stada, is a calcium channel blocker presented as an oral tablet for systemic use. It lowers elevated blood pressure and is prescribed for adults with hypertension. By relaxing vascular smooth muscle, it improves arterial compliance and reduces cardiovascular strain.

GNH USA supplies Lercanidipino Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Lercanidipine is a calcium channel blocker indicated for the management of hypertension and related blood‑pressure disorders.

- Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. - Isolated systolic hypertension: helps control elevated systolic pressure, especially in older adults. - Hypertension in the elderly: provides effective blood‑pressure reduction with once‑daily dosing.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and redness of the skin, especially on the face. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness, particularly after standing. - Tachycardia: increased heart rate. - Fatigue or general weakness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or urticaria. - Angioedema: swelling of lips, tongue, or airway. - Cardiac arrhythmias: irregular heart rhythms.

Before initiating therapy with lercanidipine, several safety considerations should be observed. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant antihypertensives: adjust doses to prevent additive hypotension. - Heart failure: evaluate cardiac status before use. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and risk of hypotension. - Grapefruit juice: can elevate drug concentration. - Other potent antihypertensives: may cause additive blood‑pressure lowering.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Diuretics: monitor electrolytes and blood pressure. - NSAIDs: may blunt antihypertensive response. - Beta‑blockers: assess for bradycardia. - Lipid‑lowering agents (e.g., statins): watch for increased statin levels.